Development
Biogen Inc.
BIIB
$138.60
$3.662.71%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -5.69% | 2.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.69% | 3.03% | |||
| Cost of Revenue | -6.26% | -43.93% | |||
| Gross Profit | -5.49% | 46.19% | |||
| SG&A Expenses | -19.21% | 40.30% | |||
| Depreciation & Amortization | 25.78% | 15.12% | |||
| Other Operating Expenses | 7.52% | -11.25% | |||
| Total Operating Expenses | -14.81% | 23.98% | |||
| Operating Income | 70.46% | -57.29% | |||
| Income Before Tax | 306.52% | -119.94% | |||
| Income Tax Expenses | 158.57% | -163.50% | |||
| Earnings from Continuing Operations | 464.42% | -111.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 300.00% | 111.76% | |||
| Net Income | 466.67% | -111.51% | |||
| EBIT | 70.46% | -57.29% | |||
| EBITDA | 52.01% | -47.32% | |||
| EPS Basic | 466.43% | -111.50% | |||
| Normalized Basic EPS | 38.21% | -55.46% | |||
| EPS Diluted | 464.26% | -111.56% | |||
| Normalized Diluted EPS | 37.45% | -55.21% | |||
| Average Basic Shares Outstanding | 0.07% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.62% | -0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||